Brian Leyland-Jones – författare
Visar alla böcker från författaren Brian Leyland-Jones. Handla med fri frakt och snabb leverans.
4 produkter
4 produkter
1 842 kr
Tillfälligt slut
Pharmacogenetics is becoming increasingly relevant in the diagnosis, treatment, and recovery of cancer patients. A major problem facing oncologists is the outstanding varied efficacy of treatment. Promising advances in pharmacogenetics have allowed the development of effective agents which will enable personalized cancer chemotherapy to become routine for the clinical practice. Written by experts in the field and combining information that is unable to be found in a single source volume, Pharmacogenetics of Breast Cancer: combines a complete overview of pharmacogenetics and how it relates to breast oncology for diagnosis, treatment, and the recovery of patients using an individualized therapy modelis the first single source reference demonstrating the application of pharmacogenetics in the care of breast cancer patientsenables physicians a coherent interpretation of the emerging science of pharmacogenetics, aiding them to incorporate individual therapies in their own practicegives practical guidance on various forms of specimen collection, tissue selection, and handling procedures
1 236 kr
Skickas inom 10-15 vardagar
Pharmacogenetics is becoming increasingly relevant in the diagnosis, treatment, and recovery of cancer patients. A major problem facing oncologists is the outstanding varied efficacy of treatment. Promising advances in pharmacogenetics have allowed the development of effective agents which will enable personalized cancer chemotherapy to become routine for the clinical practice. Written by experts in the field and combining information that is unable to be found in a single source volume, Pharmacogenetics of Breast Cancer: combines a complete overview of pharmacogenetics and how it relates to breast oncology for diagnosis, treatment, and the recovery of patients using an individualized therapy modelis the first single source reference demonstrating the application of pharmacogenetics in the care of breast cancer patientsenables physicians a coherent interpretation of the emerging science of pharmacogenetics, aiding them to incorporate individual therapies in their own practicegives practical guidance on various forms of specimen collection, tissue selection, and handling procedures
1 654 kr
Skickas inom 10-15 vardagar
In the post human-genome project era, cancer specific genomic maps are redesigning tumor taxonomy by evolving from histopathology to molecular pathology. The success of a cancer drug today is fundamentally based on the success in identifying target genes that control beneficial pathways. The overwhelming power of genomics and proteomics has enlightened researchers about the fact that the PI3K-mTOR pathway is the most commonly up-regulated signal transduction pathway in various cancers, either by virtue of its activation downstream of many cell surface growth factor receptors or by virtue of its collateral and compensatory circuitry with RAS-MAPK pathway. Oncogenic signaling in the majority of solid tumors is sustained via the PI3K-AKT-mTOR pathway. Because of its prominent role in many cancer types, the PI3K-mTOR pathway has become a major therapeutic target. The volume includes two complementary parts which address the problem of etiology and disease progression and is intended to portray the very basic mechanisms of the PI3K-AKT-mTOR signaling pathway’s involvement in various facets of the cancer, including stem cell renewal, cell metabolism, angiogenesis, genetic instability, and drug resistance. Significant progress has been made in recent years elucidating the molecular mechanism of cancer cell proliferation, angiogenesis, and drug-resistance in relation to the PI3K-mTOR pathway and this volume provides an in-depth overview of recent developments made in this area.
1 654 kr
Skickas inom 10-15 vardagar
In the post human-genome project era, cancer specific genomic maps are redesigning tumor taxonomy by evolving from histopathology to molecular pathology. The success of a cancer drug today is fundamentally based on the success in identifying target genes that control beneficial pathways. The overwhelming power of genomics and proteomics has enlightened researchers about the fact that the PI3K-mTOR pathway is the most commonly up-regulated signal transduction pathway in various cancers, either by virtue of its activation downstream of many cell surface growth factor receptors or by virtue of its collateral and compensatory circuitry with RAS-MAPK pathway. Oncogenic signaling in the majority of solid tumors is sustained via the PI3K-AKT-mTOR pathway. Because of its prominent role in many cancer types, the PI3K-mTOR pathway has become a major therapeutic target. The volume includes two complementary parts which address the problem of etiology and disease progression and is intended to portray the very basic mechanisms of the PI3K-AKT-mTOR signaling pathway’s involvement in various facets of the cancer, including stem cell renewal, cell metabolism, angiogenesis, genetic instability, and drug resistance. Significant progress has been made in recent years elucidating the molecular mechanism of cancer cell proliferation, angiogenesis, and drug-resistance in relation to the PI3K-mTOR pathway and this volume provides an in-depth overview of recent developments made in this area.